Abstract: OBJECTIVE To explore the key points of pharmaceutical care in the use of asparaginase. METHODS According to participation of clinical pharmacists in the treatment of acute lymphoblastic leukemia in children with asparaginase-associated pancreatitis, the key points of pharmaceutical care were established based on relevant guidelines and the latest evidence based medicine. RESULTS The key points of pharmaceutical care was:the earlier and rapid identification of asparaginase-associated pancreatitis; establishment and adjustment of therapeutic regimens for asparaginase-associated pancreatitis; assessment of the risk of re-exposing patients who suffered an episode of asparaginase-associated pancreatitis to asparaginase. CONCLUSION The pharmaceutical care to rapidly identify and manage asparaginase-associated pancreatitis will help ensure pediatric patients receive the maximal benefit from asparaginase therapy.